A new drug targets RAS-PI3Kα pathways without harmful side effects. It was developed using high-performance computing and AI.

Recent developments in protein-protein interactions (PPI) give hope for patients with advanced or untreatable diseases.

Exposing political desperation, Temitope Ajayi slams Atiku, Obi, and ADC allies for attempting a comeback without vision, ...

What was widely touted as a potential seismic shift in Nigeria’s political terrain turned out to be a mere political puff off ...

Beyond an inconspicuous garage door on the side of an otherwise conspicuous Snell Hall is the home of a student-staffed book ...

Zhuhai Yufan Biotechnologies Co. Ltd. has identified molecular glue degraders comprising an E3 ubiquitin protein ligase-binding agent covalently bound to a DNA-binding protein Ikaros (IKZF1)-targeting ...

The global sodium silicate market is most commonly recognized for its roles in detergents, pulp and paper, water treatment, ...

A new cancer drug candidate developed by Lawrence Livermore National Laboratory, BridgeBio Oncology Therapeutics and ...

Miki Tsuzaki, who has worked at the atelier for 22 years, specializes in binding and gold embossing. Her movements must be ...

A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating ...

MIT and Freie Universität Berlin researchers drew inspiration from mussels' gluey plaque and human mucus to create a new ...